Clinical trials: Histological Response
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not…
- Conditions
- Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma
- Trial name
- NCT04684368
- Testing
- Biospecimen Collection, Carboplatin, Etoposide
- Where
- 170 sites in United States, Australia and 2 more
- Volunteers
- 160 people
- Sponsor
- Children's Oncology Group
Melanoma
Peptide Vaccination for Patients at High Risk for Recurrent Melanoma
This study will examine the effectiveness and side effects of an experimental vaccine to prevent recurrence of melanoma. The likelihood of melanoma returning is higher in patients who have melanoma lesions deep in the skin, in…
- Trial name
- NCT00059475
- Testing
- Glycoprotein 100 (GP100): 209-217 (210M), Interleukin-2 (IL-2), Montanide ISA 51
- Where
- United States
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Squamous Cell
Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer
The purpose of this study is to collect data and evaluate how the tumor is broken down in response to standard of care cetuximab treatment by evaluating the FDG-PET/CT scans, toxicity, see how well the FDG-PET/CT scans predict…
- Trial name
- SCCHN (NCT00671437)
- Testing
- FDG-PET/CT, Cetuximab
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
This is a clinical trial testing whether the addition of one of two chemotherapy agents, dasatinib or venetoclax, can improve outcomes for children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia and…
- Conditions
- T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
- Trial name
- NCT06390319
- Testing
- Dexamethasone, Vincristine, Daunorubicin
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- St. Jude Children's Research Hospital
Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
The purpose of this pilot study will be to provide i) information on feasibility implementing an exercise intervention trial among patients with cutaneous cancers, including melanoma, squamous cell carcinoma (cuSCC), and Merkel…
- Conditions
- Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma
- Trial name
- EX-BOOST (NCT06008977)
- Testing
- Exercise Test
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- AdventHealth Translational Research Institute
Carcinoma, Small Cell
Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient
Belotecan (Camtobell, CKD-602, Chong Kun Dang Pharm., Korea) is a new camptothecin derivative, that exhibits anticancer effects by inhibiting topoisomerase I.
- Trial name
- COMBAT (NCT00826644)
- Testing
- Belotecan, Etoposide, Cisplatin
- Where
- South Korea
- Volunteers
- 147 people
- Sponsor
- Chonnam National University Hospital
Large B Cell Lymphoma
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
phase II, response-adaptive, open-label, multicenter study aiming to include 80 patients in 78 months. Patients will receive 3 cycles of epcoritamab monotherapy and, since cycle 4, they can continue with epcoritamab monotherapy…
- Trial name
- REPIFIR (NCT07126236)
- Testing
- Epcoritamab, Epcoritamab, tafasitamab and lenalidomide
- Where
- 19 sites in Spain
- Volunteers
- 80 people
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Hodgkin Disease, Non-Hodgkin Lymphoma
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
This study investigates whether the prophylactic use of moxifloxacin during high-dose chemotherapy followed by autologous stem cell transplantation reduces the incidence of clinically significant bacteremia.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Multiple Myeloma, Bacteremia
- Trial name
- MoxiProph (NCT00398411)
- Testing
- moxifloxacin
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- University of Cologne
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
5-Fluorouracil Response and Optimization STudy (The FROST Trial)
This randomized phase II trial will characterize the efficacy, adverse event (AE) profile, and safety of two regimens of 5-FU given as 2L+ treatment to patients with RM-HNSCC.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT07419464
- Testing
- 5-Fluorouracil
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Washington University School of Medicine
Recurrent Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma
An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas
This study evaluates the use of a new imaging agent called fluorodopa F 18 (18F-DOPA) with positron emission tomography/magnetic resonance imaging (PET/MRI) for assessing treatment response in patients undergoing standard of care…
- Conditions
- Recurrent Soft Tissue Sarcoma, Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma
- Trial name
- NCT05560009
- Testing
- Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Oral Squamous Cell Carcinoma, Neoadjvant Therapy
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC
To compare the pathological efficacy of neoadjuvant Toripalimab and Albumin paclitaxel /Cisplatin (TTP) with Docetaxel/ Cisplatin/ 5-flurouracil (TPF) for patients with locally advanced resectable oral squamous cell carcinoma…
- Conditions
- Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1, Chemotherapy
- Trial name
- NCT05125055
- Testing
- Toripalimab (anti-programmed death-1 inhibitor), Albumin paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
T-LGL Leukemia, NK-LGL Leukemia
Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
There is currently no standard first-line treatment for LGLL. The investigators used the TPM regimen (thalidomide + prednison + methotrexate ) to treat LGLL since 2020, enrolling a total of 54 patients and achieving an overall…
- Trial name
- NCT06530576
- Testing
- Thalidomide and methotrexate
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leukemia
S0106A, Biomarkers in Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy
RATIONALE: Studying samples of bone marrow and blood from patients with cancer in the laboratory may help doctors predict how well patients will respond to treatment.
- Trial name
- NCT01360125
- Testing
- proteomic profiling, flow cytometry, laboratory biomarker analysis
- Volunteers
- 310 people
- Sponsor
- SWOG Cancer Research Network
Systemic Mastocytosis
Evaluation of Response of Dasatinib to Treat Mastocytosis
This is a multicenter, open-label, single arm phase II non-randomized study of dasatinib in which subjects with systemic mastocytosis (SM) will be treated with a continuous regimen of dasatinib.
- Trial name
- NCT00979160
- Testing
- Dasatinib
- Where
- 12 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Federico II University
Esophageal Neoplasms
The Predictive Value of CT-PET in Esophageal Cancer
A major focus of research in oncology is to identify patients who, following induction therapy, have a complete pathologic response, presenting opportunities for novel trials, including extended therapy or non-operative…
- Trial name
- NCT02385604
- Where
- Ireland
- Volunteers
- 250 people
- Sponsor
- St. James's Hospital, Ireland
Peripheral T-cell Lymphoma
Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients
The purpose of this study is to see if pralatrexate extends response and survival following CHOP-based chemotherapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone) and if pralatrexate improves response in…
- Trial name
- NCT01420679
- Testing
- Pralatrexate Injection
- Where
- 55 sites in United States, Australia and 11 more
- Volunteers
- 21 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Breast Neoplasms, Breast Cancer
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early…
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma
- Trial name
- I-SPY (NCT01042379)
- Testing
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin
- Where
- 42 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Hepatocellular Carcinoma
Survival Analysis of Surgical Resection Versus Observation in Patients With Initially uHCC Achieving CR After Systemic Therapy
This study aims to further explore the survival benefits of surgical resection after achieving CR in initial uHCC after systemic treatment and the timing of discontinuing systemic treatment
- Trial name
- NCT07290764
- Testing
- Surgery
- Where
- China
- Volunteers
- 729 people
- Sponsor
- Fujian Provincial Hospital
Healthy Volunteer, Prostate Cancer
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Earlier detection of disease recurrence will enable greater treatment options and has strong potential to improve patient outcomes.
- Conditions
- Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer
- Trial name
- NCT04354064
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Glioblastoma
Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme
This study is for subjects with a diagnosis of a brain tumor called glioblastoma that is being treated with bevacizumab. This study will use a new MRI technique to compare the images of blood vessels and tumor structure to the…
- Trial name
- NCT01604590
- Testing
- Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Medical University of South Carolina
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.